Who funded the research behind the Oxford–AstraZeneca Covid-19 vaccine
Bibliographic Data
OBJECTIVES: The Oxford-AstraZeneca COVID-19 vaccine (ChAdOx1 nCoV-19, Vaxzevira or Covishield) builds on two decades of research and development (R&D) into chimpanzee adenovirus-vectored vaccine (ChAdOx) technology at the University of Oxford. This study aimed to approximate the funding for the R&D of ChAdOx and the Oxford-AstraZeneca vaccine and to assess the transparency of funding reporting mechanisms. METHODS: We conducted a scoping review and publication history analysis of the principal investigators to reconstruct R&D funding the ChAdOx technology. We matched award numbers with publicly accessible grant databases. We filed freedom of information (FOI) requests to the University of Oxford for the disclosure of all grants for ChAdOx R&D. Government funders from overseas (including the European Union) were mentioned 158 times (27.4%), the UK government 147 (25.5%) and charitable funders 138 (23.9%). Grant award numbers were identified for 215 (37.3%) mentions; amounts were publicly available for 121 (21.0%). Based on the FOIs, until December 2019, the biggest funders of ChAdOx R&D were the European Commission (34.0%), Wellcome Trust (20.4%) and Coalition for Epidemic Preparedness Innovations (17.5%). Since January 2020, the UK government contributed 95.5% of funding identified. The total identified R&D funding was £104 226 076 reported in the FOIs and £228 466 771 reconstructed from the literature search. CONCLUSION: Our study approximates that public and charitable financing accounted for 97%-99% of identifiable funding for the ChAdOx vaccine technology research at the University of Oxford underlying the Oxford-AstraZeneca vaccine until autumn 2020. We encountered a lack of transparency in research funding reporting
2019-20 coronavirus outbreak · Disease · Political science · Immune responses and vaccinations · Medicine · SARS-CoV-2 and COVID-19 Research · Virus-based gene therapy research · Internal Medicine · Virology
Wars and sweets
Covid-19 Vaccines in India
Financing Covid-19 vaccination in sub-Saharan Africa
From Public Labs to Private Firms
Open science, open innovation? The role of open access in patenting activity
Global Covid-19 Vaccine Inequity
Lessons for the HIV response from structural innovations catalysed by Covid-19
Towards a new model of global health justice
Technological impact of funded research
Funding Covid-19 research
The WTO and the Covid‐19 “Vaccine Apartheid”
Covid-19 vaccine apartheid and the failure of global cooperation
Global inequities in access to Covid-19 health products and technologies
Scarcity, Property Rights, Irresponsibility
Achieving equitable access to health technologies during a pandemic
University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic
Which roads lead to access? A global landscape of six Covid-19 vaccine innovation models
Prioritising human rights principles in synthetic biology innovation and patenting
Challenges in ensuring global access to Covid-19 vaccines
Rayyan—a web and mobile app for systematic reviews
Structural violence and the biomedical innovation system
Making a Covid-19 vaccine that works for everyone
University patenting and licensing practices in the United Kingdom during the first year of the Covid-19 pandemic
| Citations per year | 4.5 |
|---|---|
| Citation span | 2022 - 2026 (5) |
| Highly cited | No |